Based on the latest data from August 2025, CVS is currently trading at $73.15, positioning the stock in the "Fair" valuation zone between the 14.0x and 19.8x PE multiples. Specifically, the stock price sits above the 14.0x PE boundary of $50.26 but well below the 19.8x PE boundary of $71.12, indicating the stock is approaching the upper end of fair value territory. This current positioning suggests CVS is reasonably valued from a PE ratio perspective, though investors should monitor for potential movement into higher valuation zones. Analyzing the historical trend reveals significant valuation fluctuations over the past five years. From 2020 to early 2022, CVS experienced substantial valuation expansion, with the stock price climbing from around $60 to over $90, moving from the Fair zone into Watch and occasionally Overvalued territories above the 19.8x PE multiple. A notable valuation contraction occurred from late 2022 through 2024, where the stock fell dramatically to as low as $47.93 in December 2024, briefly touching the Undervalued zone below the 8.2x PE boundary of $29.97. The recent recovery to $73.15 represents a significant rebound of over 50% from those December lows, bringing the stock back to more normalized Fair valuation levels. This volatility pattern suggests CVS has experienced both significant overvaluation during the 2021-2022 period and undervaluation in late 2024, with the current position indicating a return to more reasonable PE multiples.